Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeAuthor: Jeffrey Neal Johnson. Posted: 12/31/2025. 
Quick Look - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market of 2025 will be remembered for its extremes. Investors poured billions into technology giants and manufacturers of weight-loss drugs, while traditional pharmaceutical leaders were largely left behind. Nowhere is that contrast clearer than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finishes the year as one of the most unloved names in the S&P 500. For the casual observer, the pessimism appears justified: the firm has spent the last two years battling a perfect storm. Revenue from COVID-19 products evaporated faster than many expected, several high-profile pipeline candidates failed in clinical trials, and activist investors waged a public campaign against management. Buy This AI Stock Tomorrow Morning?
A former hedge fund manager known for spotting early winners is sounding the alarm once again. He called Netflix at $7.78 (up 4,200% since), Apple at $0.35 (up 20,000%), and Amazon at a split-adjust $2.41 (up 3,200%). Now he's turning his focus to a little-known AI company that just earned a near-perfect score in his new proprietary stock grading system. In a brand-new presentation, he reveals the name, ticker symbol, and why this could be the smartest AI move of the year... especially if you're over 50. Click here to watch it before word gets out. But investing often requires looking where others do not. With activist Starboard Value exiting in November and management providing a realistic reset to guidance, the worst of that storm may be behind Pfizer. The bad news is out, and Pfizer’s stock price has likely found a floor. As we enter 2026, Pfizer presents a rare setup: a blue-chip company trading at a distressed valuation, paying a meaningful dividend while it quietly rebuilds its growth profile. The Mathematical Case: Why the Price Is Wrong For value investors, the case for Pfizer is straightforward. The market is pricing the company as if its earnings will permanently shrink, creating a large disconnect between the share price and the company's underlying cash generation. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio of roughly 8.6x. By comparison, the average pharmaceutical company trades at 15x–20x earnings, and high-growth peers such as Eli Lilly (NYSE: LLY) command substantially higher multiples. When a company is valued at 8.6x forward earnings, the market is effectively assigning it near-zero growth expectations. That sets a low bar: Pfizer does not need a blockbuster turnaround to see its stock re-rate—only proof that earnings are stabilizing. Any positive surprise could prompt multiple expansion as the market readjusts toward industry norms. The Dividend Shield While investors wait for a repricing, they are paid to hold the shares. - Annual payout: $1.72 per share.
- Current yield: Approximately 6.9%.
That yield is roughly four times the S&P 500 average and serves as a margin of safety. Even if the stock price remains unchanged through 2026, a near-7% dividend provides a strong baseline return that outpaces most savings accounts and government bonds. Management is supporting the dividend through a roughly $4 billion cost-savings plan. By trimming administrative bloat and optimizing manufacturing, the company is preserving cash flow to keep those quarterly checks flowing. The New Foundation: Oncology Takes the Lead One of the biggest criticisms of Pfizer is the growth gap left by declining COVID revenue. To address that, the company has pivoted aggressively toward oncology. The Guided-Missile Approach The centerpiece of Pfizer’s oncology push is the Seagen acquisition and its work in Antibody-Drug Conjugates (ADCs). Where traditional chemotherapy is indiscriminate, ADCs act like guided missiles—targeting cancer cells and delivering toxic payloads directly, which can spare healthy tissue. This approach is already contributing meaningful revenue. The Seagen portfolio contributed approximately $3.4 billion in 2024 and had previously generated about $2.75 billion in the first three quarters after the acquisition, driven largely by Padcev sales. Navigating the Bumps The road has not been without setbacks. In December 2025, Pfizer reported a safety signal in a trial extension for Hympavzi that involved a patient death; the news rattled the stock briefly. That incident, however, does not negate the larger thesis. Pfizer’s oncology pipeline is deep—with more than 60 programs in development—and the company has continued to bolster that pipeline, for example by licensing a promising bispecific antibody from 3SBio. Catching Up: The Strategy for Weight Loss After its internal oral candidate Danuglipron failed to progress in early 2025, Wall Street largely wrote Pfizer off in the weight-loss drug race. Management did not concede defeat. Instead, Pfizer bought back into the market through two strategic moves late in 2025. The Injectable Strategy (Metsera) In November, Pfizer completed the Metsera acquisition for about $7 billion, acquiring MET-097i, a next-generation injectable with the potential for monthly dosing—an advantage versus the weekly injections used by current market leaders. The Oral Strategy (YaoPharma) Pfizer also licensed a small-molecule GLP-1 candidate from YaoPharma, recognizing that many patients prefer an oral option to injections. Why This Matters The market currently assigns little to no value to Pfizer’s obesity pipeline, effectively treating the opportunity as lost. That creates a free option for investors: with expectations at rock bottom, any clinical or commercial success from the Metsera or YaoPharma assets would be pure upside. Pfizer doesn't need to be first—capturing even a slice of a market projected to reach roughly $100 billion would materially change the company’s outlook. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 in transition but with a materially strengthened balance sheet. Management has set a revenue floor of about $61 billion for 2026, a realistic target that reduces uncertainty that dogged the stock in prior years. For investors, the math is simple. At roughly $25 per share, downside is cushioned by a high dividend and valuations near historic lows. The upside is meaningful: continued oncology growth or positive developments in the weight-loss pipeline could trigger a sharp repricing. The unloved stocks of one year often become the standouts of the next. With the activist drama behind it and the balance sheet stabilized, Pfizer has shifted from a falling knife into a potential core holding for value-oriented portfolios. 2026 may be the year the sleeping giant wakes up.
| 
Post a Comment
Post a Comment